LGBTQA+ individuals who have used classic psychedelics emphasize that healthcare providers must examine their own biases and learn relevant language to build trust and ensure safety during preparation sessions. Providers should adopt a flexible, client-led approach when supporting identity exploration, particularly around returning from a 'universal consciousness' experience. They also need to thoughtfully modulate their presence during clients' psychedelic experiences. These findings highlight the need for psychedelic-assisted therapy protocols that acknowledge the varied experiences and needs of LGBTQA+ communities.
An analysis of 225 Reddit posts from trans individuals describes how psychedelic experiences can both help and harm. Psychedelic-induced altered states can lead to self-acceptance, gender euphoria, and gender realization, and psychological release during trips can facilitate a journey of self-acceptance. These experiences can function as a catalyst for change but can also simultaneously support and exacerbate gender dysphoria. The findings highlight a duality in psychedelics for trans people, with both healing qualities (e.g., gender euphoria, self-acceptance) and harming qualities (e.g., exacerbated dysphoria and grief). Clinical applications should consider this duality to inform responsive and affirming psychedelic-assisted psychotherapy protocols.
Psychedelic-assisted therapies are re-emerging as credible options in psychological care, addressing the high global burden of mental ill-health and limited response to first-line treatments. Classic and atypical compounds like psilocybin and MDMA act through 5-HT2A-mediated effects, default mode network modulation, increased global connectivity, and a time-limited neuroplasticity window that psychotherapy can harness. Evidence supports applications for treatment-resistant depression, PTSD, end-of-life anxiety, and addictions. Positive outcomes depend on the therapeutic frame—preparation, supported dosing, and structured integration—not medication alone. Risks, contraindications, regulatory realities, and cultural-ethical considerations, including Indigenous knowledge and equity of access, are addressed.